跳至主要内容
临床试验/NCT00161915
NCT00161915已完成3 期

Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices

Baxter Healthcare Corporation24 个研究点 分布在 1 个国家开始时间: 2000年12月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
试验地点
24

研究概览

简要总结

The purpose of this study was to assess whether endoscopic sclerotherapy with Fibrin Sealant was superior to ligature, with or without Polidocanol, in achieving hemostasis in bleeding esophageal varices and preventing rebleeding. Therapeutic success was defined as survival of the first seven days without clinically significant bleeding.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Included in the study were patients with proven bleeding from esophageal varices due to liver cirrhosis:
  • with a minimum age of 18 years,
  • with bleeding symptoms (hematemesis, melena, hematochezia, hypotension, tachycardia) that had lasted not longer than 48 hours prior to hospital admission,
  • who were expected to be hospitalized for at least seven days,
  • who agreed to participate in the study.
  • Randomization did not take place if another therapy was medically indicated for any reason.

排除标准

  • Patients were excluded from the study:
  • in whom introduction of an endoscope was not possible for technical reasons,
  • who had received an alternative endoscopic treatment to eradicate varices during the last three months (sclerotherapy, ligation),
  • who had proven additional fundus bleeding from varices or bleeding from a hypertensive gastropathy,
  • who had end stage tumor disease or end stage liver cirrhosis (Child Pugh class C with organ complications, such as hepatonephric syndrome, infected ascites etc.),
  • who were pregnant or breast feeding,
  • who had a known pulmonary disease combined with restricted lung function or right ventricular failure,
  • who had congenital or acquired coagulopathies of non-hepatic origin,
  • who were currently participating or had participated in another study during the past 30 days or had already been included in this study once,
  • who were treated with drugs to decrease portal vein pressure (somatostatin, somatostatin analogs, terlipressin, glycylpressin, except β-blockers and nitrates),
  • who had shown an allergic reaction to thrombin or aprotinin,
  • who had a heparin-induced thrombocytopenia Type I or Type II.

研究者

申办方类型
Industry

研究点 (24)

Loading locations...

相似试验